|
CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. |
| |
|
Consulting or Advisory Role - Third Rock Ventures |
Research Funding - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech |
| |
|
Consulting or Advisory Role - ARIAD; Bristol-Myers Squibb; Janssen |
Research Funding - ARIAD (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Incyte (Inst); Pfizer (Inst) |
| |
|
Honoraria - Clovis Oncology; Genentech |
Research Funding - ArQule; Astex Pharmaceuticals; AstraZeneca/MedImmune; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; Lilly; Synta |
| |
|
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; Merck KGaA |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Merck (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck |
Other Relationship - Bristol-Myers Squibb |
| |
|
Honoraria - Bristol-Myers Squibb; Celgene |
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly |
Research Funding - Millennium (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly |
| |
|
Honoraria - Amgen; Astellas Pharma; Emergent BioSolutions; Merck; Novartis |
Consulting or Advisory Role - Amgen; Emergent BioSolutions; Merck; Novartis |
Research Funding - Genentech (Inst); Incyte (Inst); Merck (Inst); NCCN (Inst); Novartis (Inst); Pfizer (Inst); VentiRx (Inst) |
Travel, Accommodations, Expenses - Merck; Novartis |
| |
|
Honoraria - Bristol-Myers Squibb; Celgene; Heat Biologics |
Travel, Accommodations, Expenses - AstraZeneca |
| |
|
Stock and Other Ownership Interests - Gilead Sciences |
Research Funding - ArQule (Inst); BerGenBio (Inst); Celgene (Inst); Genentech (Inst); ImClone Systems (Inst); Immunogen (Inst); Synta (Inst) |
Patents, Royalties, Other Intellectual Property - Royalties from Decision Support in Medicine from the Clinical Decision Support--Oncology on-line program.; Royalties from Oxford University Press from two books. |
Travel, Accommodations, Expenses - ArQule; Lilly; Lilly |
| |
|
Honoraria - AstraZeneca; AstraZeneca/MedImmune; Bayer; BetaPharma; Boehringer Ingelheim; Bristol-Myers Squibb; Roche Canada |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Pfizer |
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst) |
| |
|
Stock and Other Ownership Interests - AstraZeneca; Lilly |
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; Merck/Schering Plough; Roche/Genentech |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Recombio; Synta |
Research Funding - Boehringer Ingelheim (Inst) |
| |
|
No Relationships to Disclose |
| |
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
| |
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
| |
|
No Relationships to Disclose |
| |
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
| |
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck |